GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Healius Ltd (ASX:HLS) » Definitions » Debt-to-EBITDA

Healius (ASX:HLS) Debt-to-EBITDA : -1.68 (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Healius Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Healius's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$263 Mil. Healius's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1,352 Mil. Healius's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-960 Mil. Healius's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.68.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Healius's Debt-to-EBITDA or its related term are showing as below:

ASX:HLS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -19.3   Med: 3.19   Max: 6.61
Current: -2.38

During the past 13 years, the highest Debt-to-EBITDA Ratio of Healius was 6.61. The lowest was -19.30. And the median was 3.19.

ASX:HLS's Debt-to-EBITDA is ranked worse than
100% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.915 vs ASX:HLS: -2.38

Healius Debt-to-EBITDA Historical Data

The historical data trend for Healius's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healius Debt-to-EBITDA Chart

Healius Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.29 6.61 3.06 2.50 -19.30

Healius Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 3.84 8.33 -4.44 -1.68

Competitive Comparison of Healius's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Healius's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healius's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Healius's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Healius's Debt-to-EBITDA falls into.



Healius Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Healius's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(263 + 1503) / -91.5
=-19.30

Healius's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(263.2 + 1352.2) / -960
=-1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Healius  (ASX:HLS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Healius Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Healius's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Healius (ASX:HLS) Business Description

Traded in Other Exchanges
N/A
Address
161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider and third-largest diagnostic imaging provider. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.

Healius (ASX:HLS) Headlines

No Headlines